Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Overview of attention for article published in The Lancet Diabetes & Endocrinology, October 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news: 11 news outlets
blogs: 1 blog

twitter: 16 X users
f1000: 1 research highlight platform

Readers on

mendeley: 196 Mendeley

So far, Altmetric has seen 20 X posts from 16 X users, with an upper bound of 88,457 followers.

New2Trip: Odanacatib for treatment of postmenopausal osteoporosis: results of LOFT multicentre, randomised, double-blind, placebo-controlled trial & LOFT Extension study https://t.co/zTC71iFqxR

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 16 additional X posts.